FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003259770> ?p ?o ?g. }

• W2003259770 endingPage "982" @default.
• W2003259770 startingPage "976" @default.
• W2003259770 abstract "Objective To assess the efficacy and safety of mitomycin C in the treatment of ocular surface squamous neoplasia. Design Prospective, randomized, controlled, masked, single-center trial. Participants Forty-eight consecutive patients with biopsy-proven noninvasive ocular surface squamous neoplasia. Intervention Mitomycin C (0.4 mg/ml) or a placebo was administered as 1 drop 4 times a day for 3 weeks, with crossover of drops if there was no regression within 6 weeks. Main Outcome Measures Successful treatment was measured as complete resolution of the neoplasia by slit-lamp examination within 6 to 8 weeks of treatment, with a secondary end point of histological resolution by 6 weeks. Results None of 20 in the placebo group resolved clinically, whereas 24 of 26 in the mitomycin group resolved, giving a relative resolution rate of mitomycin versus placebo of 40.87 (95% confidence interval [CI], 1.01–1656.8). There were no complications. There was no statistical treatment effect on histological resolution, with a resolution rate of mitomycin versus placebo of 1.37 (95% CI, 0.34–5.42). Conclusions Mitomycin C (0.4 mg/ml) eyedrops used 4 times a day for 3 weeks is an effective agent to cause early clinical resolution of noninvasive ocular surface squamous neoplasia. To assess the efficacy and safety of mitomycin C in the treatment of ocular surface squamous neoplasia. Prospective, randomized, controlled, masked, single-center trial. Forty-eight consecutive patients with biopsy-proven noninvasive ocular surface squamous neoplasia. Mitomycin C (0.4 mg/ml) or a placebo was administered as 1 drop 4 times a day for 3 weeks, with crossover of drops if there was no regression within 6 weeks. Successful treatment was measured as complete resolution of the neoplasia by slit-lamp examination within 6 to 8 weeks of treatment, with a secondary end point of histological resolution by 6 weeks. None of 20 in the placebo group resolved clinically, whereas 24 of 26 in the mitomycin group resolved, giving a relative resolution rate of mitomycin versus placebo of 40.87 (95% confidence interval [CI], 1.01–1656.8). There were no complications. There was no statistical treatment effect on histological resolution, with a resolution rate of mitomycin versus placebo of 1.37 (95% CI, 0.34–5.42). Mitomycin C (0.4 mg/ml) eyedrops used 4 times a day for 3 weeks is an effective agent to cause early clinical resolution of noninvasive ocular surface squamous neoplasia." @default.
• W2003259770 created "2016-06-24" @default.
• W2003259770 creator A5026508489 @default.
• W2003259770 date "2007-05-01" @default.
• W2003259770 modified "2023-09-26" @default.
• W2003259770 title "Randomized Controlled Trial of Topical Mitomycin C for Ocular Surface Squamous Neoplasia" @default.
• W2003259770 cites W1568451052 @default.
• W2003259770 cites W1605506735 @default.
• W2003259770 cites W1899887006 @default.
• W2003259770 cites W1964045619 @default.
• W2003259770 cites W1979799582 @default.
• W2003259770 cites W1988937122 @default.
• W2003259770 cites W1989533997 @default.
• W2003259770 cites W1991093938 @default.
• W2003259770 cites W1995834476 @default.
• W2003259770 cites W1996765031 @default.
• W2003259770 cites W1997647595 @default.
• W2003259770 cites W2009377629 @default.
• W2003259770 cites W2013313809 @default.
• W2003259770 cites W2029974519 @default.
• W2003259770 cites W2033409063 @default.
• W2003259770 cites W2052377972 @default.
• W2003259770 cites W2053443907 @default.
• W2003259770 cites W2056194811 @default.
• W2003259770 cites W2059191805 @default.
• W2003259770 cites W2062453319 @default.
• W2003259770 cites W2073693917 @default.
• W2003259770 cites W2074780495 @default.
• W2003259770 cites W2075659930 @default.
• W2003259770 cites W2088480894 @default.
• W2003259770 cites W2091387813 @default.
• W2003259770 cites W2094201427 @default.
• W2003259770 cites W2099629617 @default.
• W2003259770 cites W2104455052 @default.
• W2003259770 cites W2109877842 @default.
• W2003259770 cites W2113583453 @default.
• W2003259770 cites W2123993675 @default.
• W2003259770 cites W2127050151 @default.
• W2003259770 cites W2127187974 @default.
• W2003259770 cites W2165669996 @default.
• W2003259770 cites W2168231114 @default.
• W2003259770 cites W2326725409 @default.
• W2003259770 cites W4247557862 @default.
• W2003259770 doi "https://doi.org/10.1016/j.ophtha.2006.09.026" @default.
• W2003259770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17241666" @default.
• W2003259770 hasPublicationYear "2007" @default.
• W2003259770 type Work @default.
• W2003259770 sameAs 2003259770 @default.
• W2003259770 citedByCount "72" @default.
• W2003259770 countsByYear W20032597702012 @default.
• W2003259770 countsByYear W20032597702013 @default.
• W2003259770 countsByYear W20032597702014 @default.
• W2003259770 countsByYear W20032597702015 @default.
• W2003259770 countsByYear W20032597702016 @default.
• W2003259770 countsByYear W20032597702017 @default.
• W2003259770 countsByYear W20032597702018 @default.
• W2003259770 countsByYear W20032597702019 @default.
• W2003259770 countsByYear W20032597702020 @default.
• W2003259770 countsByYear W20032597702021 @default.
• W2003259770 countsByYear W20032597702022 @default.
• W2003259770 countsByYear W20032597702023 @default.
• W2003259770 crossrefType "journal-article" @default.
• W2003259770 hasAuthorship W2003259770A5026508489 @default.
• W2003259770 hasConcept C126322002 @default.
• W2003259770 hasConcept C141071460 @default.
• W2003259770 hasConcept C142724271 @default.
• W2003259770 hasConcept C168563851 @default.
• W2003259770 hasConcept C188816634 @default.
• W2003259770 hasConcept C204787440 @default.
• W2003259770 hasConcept C27081682 @default.
• W2003259770 hasConcept C2779338040 @default.
• W2003259770 hasConcept C44249647 @default.
• W2003259770 hasConcept C71924100 @default.
• W2003259770 hasConcept C87813604 @default.
• W2003259770 hasConceptScore W2003259770C126322002 @default.
• W2003259770 hasConceptScore W2003259770C141071460 @default.
• W2003259770 hasConceptScore W2003259770C142724271 @default.
• W2003259770 hasConceptScore W2003259770C168563851 @default.
• W2003259770 hasConceptScore W2003259770C188816634 @default.
• W2003259770 hasConceptScore W2003259770C204787440 @default.
• W2003259770 hasConceptScore W2003259770C27081682 @default.
• W2003259770 hasConceptScore W2003259770C2779338040 @default.
• W2003259770 hasConceptScore W2003259770C44249647 @default.
• W2003259770 hasConceptScore W2003259770C71924100 @default.
• W2003259770 hasConceptScore W2003259770C87813604 @default.
• W2003259770 hasIssue "5" @default.
• W2003259770 hasLocation W20032597701 @default.
• W2003259770 hasLocation W20032597702 @default.
• W2003259770 hasOpenAccess W2003259770 @default.
• W2003259770 hasPrimaryLocation W20032597701 @default.
• W2003259770 hasRelatedWork W113810927 @default.
• W2003259770 hasRelatedWork W1586374228 @default.
• W2003259770 hasRelatedWork W2003938723 @default.
• W2003259770 hasRelatedWork W2047967234 @default.
• W2003259770 hasRelatedWork W2118496982 @default.
• W2003259770 hasRelatedWork W2364998975 @default.
• W2003259770 hasRelatedWork W2369162477 @default.
• W2003259770 hasRelatedWork W2439875401 @default.

• next